1. Protalix will present at the H.C. Wainwright conference in September. 2. CEO Dror Bashan will speak on September 8 at the event. 3. Protalix focuses on plant cell-based therapeutic protein development. 4. Company's product Elfabrio gained FDA approval in May 2023. 5. Protalix's pipeline includes candidates for gout and NETs-related diseases.
Company presentations often boost investor confidence and attract new interest, similar to other biotech firms that saw price increases post-presentation. Past examples include presentations by companies like Moderna and BioNTech leading to significant stock appreciation.
The article highlights an upcoming event that could significantly impact stock perception, especially in a positive direction given recent regulatory approvals.
The impact from the conference is expected to be immediate and seen in trading following the presentation. Short-term volatility is typical as investors react to news.
CARMIEL, Israel, Sept. 2, 2025 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American:PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell–based protein expression system, today announced that Dror Bashan, the Company's President and Chief Executive Officer, will present at the H.C. Wainwright 27th Annual Global Investment Conference which is being held on September 8–10, 2025 at the Lotte New York Palace Hotel, New York City, NY.
Mr. Bashan will present on Monday, September 8, at 3:30 p.m. Eastern Daylight Time (EDT) in the Holmes II Room, Fourth Floor. Management will participate in one-on-one meetings throughout the conference with registered investor attendees.
About Protalix BioTherapeutics, Inc.
Protalix is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx. It is the first company to gain U.S. Food and Drug Administration (FDA) approval of a protein produced through plant cell-based in suspension expression system. This unique expression system represents a new method for developing recombinant proteins in an industrial-scale manner. Protalix has licensed to Pfizer Inc. the worldwide development and commercialization rights to taliglucerase alfa for the treatment of Gaucher disease, Protalix's first product manufactured through ProCellEx, excluding in Brazil, where Protalix retains full rights. Protalix's second product, Elfabrio®, was approved by both the FDA and the European Medicines Agency in May 2023.
Protalix has partnered with Chiesi Farmaceutici S.p.A. for the global development and commercialization of Elfabrio. Protalix's development pipeline consists of proprietary versions of recombinant therapeutic proteins that target established pharmaceutical markets, including the following product candidates: PRX–115, a plant cell-expressed recombinant PEGylated uricase for the treatment of uncontrolled gout; PRX–119, a plant cell-expressed long acting DNase I for the treatment of NETs-related diseases; and others.
Investor Contact
Mike Moyer, Managing Director
LifeSci Advisors
+1-617-308-4306
mmoyer@lifesciadvisors.com
Logo: https://mma.prnewswire.com/media/999479/Protalix_Biotherapeutics_Logo.jpg
View original content:https://www.prnewswire.com/news-releases/protalix-biotherapeutics-to-present-at-the-hc-wainwright-27th-annual-global-investment-conference-302543639.html
SOURCE Protalix Biotherapeutics Inc.